Grants per year
Personal profile
Research Interests
Hodgkin's disease, Leukemia, Lymphoma
Certifications and Licenses
| Internal Medicine | |
| Hematology | |
| Medical Oncology |
Training Experience
| 1978 | Internship, University of Chicago |
| 1980 | Residency, University of Chicago Hospitals |
| 1981 | Fellowship, Columbia Presbyterian Hospital in NYC |
| 1982 | Fellowship, Northwestern University, McGaw Medical Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, University of Pennsylvania
… → 1977
Research interests keywords
- Hematology
- Non-Hodgkin's Lymphoma
Fingerprint
Dive into the research topics where Jane Norma Winter is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #NU 16H08: Phase II study of PET-directed frontline therapy with pembrolizumab and AVD for patients with classical Hodgkin lymphoma
Winter, J. N. (PD/PI)
Merck Sharp & Dohme Corporation
8/10/17 → 8/10/26
Project: Research project
-
Prot #NU 16H07: Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Winter, J. N. (PD/PI)
Merck Sharp & Dohme Corporation
4/3/17 → 4/3/26
Project: Research project
-
Prot #COMB157BUS25T//NU 10H06: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Ma, S. (PD/PI), Frankfurt, O. (Co-PD/PI), Gordon, L. I. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)
Novartis Pharmaceuticals Corporation
4/21/11 → 12/31/25
Project: Research project
-
Prot #MK-3475-C11-01: Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
Winter, J. N. (PD/PI)
Merck Sharp & Dohme Corporation
2/24/22 → 2/24/25
Project: Research project
-
Mosunetuzumab next up to bat … is it a home run?
Karmali, R. & Winter, J. N., Feb 13 2025, In: Blood. 145, 7, p. 655-657 3 p.Research output: Contribution to journal › Editorial › peer-review
-
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Grunblatt, E., Meng, Z., Baldridge, A. S., Patel, N. P., Stanisic, A., Feinstein, M. J., Rao, A., Gordon, L. I., Winter, J. N., Ma, S., Mehta, J., Singhal, S., Karmali, R. & Akhter, N., 2025, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Article › peer-review
-
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen
Karmali, R., Galvez, C., Hamadani, M., Gordon, L., Winter, J., Ma, S., Nelson, V., Fenske, T. S., Shah, N. N., Jagadeesh, D., Klein, A., Helenowski, I., Chen, R., Mi, X., Petrich, A., Evens, A. M. & Pro, B., Apr 9 2024, In: Blood Advances. 8, 7, p. 1612-1620 9 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
Karmali, R., Machhi, R., Epperla, N., Shouse, G., Romancik, J., Moyo, T. K., Kenkre, V., Ollila, T. A., Fitzgerald, L., Hess, B., David, K., Roy, I., Zurko, J., Chowdhury, S. M., Annunzio, K., Ferdman, R., Bhansali, R. S., Harris, E. I., Liu, J. & Nizamuddin, I. & 11 others, , May 28 2024, In: Blood Advances. 8, 10, p. 2592-2599 8 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations -
Predicting outcomes in CNS lymphoma with ctDNA
Winter, J. N. & Ferreri, A. J. M., Feb 8 2024, In: Blood. 143, 6, p. 478-480 3 p.Research output: Contribution to journal › Editorial › peer-review
1 Scopus citations
Datasets
-
MOESM3 of Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Xu-Monette, Z. Y. (Creator), Li, J. (Creator), Xia, Y. (Creator), Crossley, B. (Creator), Bremel, R. D. (Creator), Miao, Y. (Creator), Xiao, M. (Creator), Snyder, T. (Creator), Manyam, G. C. (Creator), Tan, X. (Creator), Zhang, H. (Creator), Visco, C. (Creator), Tzankov, A. (Creator), Dybkaer, K. (Creator), Bhagat, G. (Creator), Tam, W. (Creator), You, H. (Creator), Hsi, E. D. (Creator), Van Krieken, J. H. (Contributor), Huh, J. (Creator), Ponzoni, M. (Creator), Ferreri, A. J. M. (Creator), Møller, M. B. (Creator), Piris, M. A. (Creator), Winter, J. N. (Creator), Medeiros, J. T. (Creator), Xu, B. (Creator), Li, Y. (Creator), Kirsch, I. (Creator) & Young, K. H. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.10027217, https://springernature.figshare.com/articles/dataset/MOESM3_of_Immunoglobulin_somatic_hypermutation_has_clinical_impact_in_DLBCL_and_potential_implications_for_immune_checkpoint_blockade_and_neoantigen-based_immunotherapies/10027217
Dataset
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Deng, M. (Creator), Zhang, M. (Creator), Xu-Monette, Z. Y. (Creator), Pham, L. V. (Creator), Tzankov, A. (Creator), Visco, C. (Creator), Fang, X. (Creator), Bhagat, G. (Creator), Zhu, F. (Creator), Dybkaer, K. (Creator), Chiu, A. (Creator), Tam, W. (Creator), Zu, Y. (Creator), Hsi, E. D. (Creator), Choi, W. W. L. (Creator), Huh, J. (Creator), Ponzoni, M. (Creator), Ferreri, A. J. M. (Creator), Møller, M. B. (Creator), Parsons, B. M. (Creator), van Krieken, J. H. (Creator), Piris, M. A. (Creator), Winter, J. N. (Creator), Hagemeister, F. (Creator), Alinari, L. (Creator), Li, Y. (Creator), Andreeff, M. (Creator), Xu, B. (Creator) & Young, K. H. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5197431.v1, https://springernature.figshare.com/collections/XPO1_expression_worsens_the_prognosis_of_unfavorable_DLBCL_that_can_be_effectively_targeted_by_selinexor_in_the_absence_of_mutant_p53/5197431/1
Dataset
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
Xu-Monette, Z. Y. (Creator), Li, J. (Creator), Xia, Y. (Creator), Crossley, B. (Creator), Bremel, R. D. (Creator), Miao, Y. (Creator), Xiao, M. (Creator), Snyder, T. (Creator), Manyam, G. C. (Creator), Tan, X. (Creator), Zhang, H. (Creator), Visco, C. (Creator), Tzankov, A. (Creator), Dybkaer, K. (Creator), Bhagat, G. (Creator), Tam, W. (Creator), You, H. (Creator), Hsi, E. D. (Creator), Van Krieken, J. H. (Contributor), Huh, J. (Creator), Ponzoni, M. (Creator), Ferreri, A. J. M. (Creator), Møller, M. B. (Creator), Piris, M. A. (Creator), Winter, J. N. (Creator), Medeiros, J. T. (Creator), Xu, B. (Creator), Li, Y. (Creator), Kirsch, I. (Creator) & Young, K. H. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4708682, https://springernature.figshare.com/collections/Immunoglobulin_somatic_hypermutation_has_clinical_impact_in_DLBCL_and_potential_implications_for_immune_checkpoint_blockade_and_neoantigen-based_immunotherapies/4708682
Dataset